Amplia and ANZGOG enter into agreement to conduct a clinical study in ovarian cancer evaluating narmafotinib in combination with standard-of-care chemotherapy Ovarian cancer represents a major target ...

For more information or to attend the conference, click here.

WOBURN, Mass., May 08, 2026 (GLOBE NEWSWIRE) -- iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists requiring biospecimens for medical ...

White Oak, Md., May 08, 2026 (GLOBE NEWSWIRE) -- The U.S. Food and Drug Administration today issued a final guidance for industry, Postapproval Pregnancy Safety Studies, with recommendations on ...

Securities holders wishing to participate remotely, virtually and in real time, to the Company's annual and extraordinary shareholders’ meetings are required to confirm their participation and ...

The Company will host a conference call and webcast at 8:30 AM ET that morning to review financial results and provide a corporate update on recent progress across its iNKT cell therapy platform, ...

Morelifemvmt today announced the first two speaker lineup, programming and partner roster for the More Life Summit, a premium two-day longevity, performance, faith and purpose experience taking place ...

In parallel, the Company continues to be actively engaged in further discussions with potential partners and strategic advisors to identify, review and evaluate potential strategic alternatives ...

On March 25, 2026, the Company received biocidal product authorization from the Dutch regulatory authority (ctgb), marking TOMI’s first product approval within a European Union member state and ...

EB612: First-in-Class Oral Long-Acting PTH (1-34) Replacement Tablet for Hypoparathyroidism ...

The laromestorcel HLHS program has received three FDA designations: Orphan Drug designation, Fast Track designation and Rare Pediatric Disease designation. Under the Rare Pediatric Disease designation ...

DEXTENZA ® is a registered trademark of Ocular Therapeutix, Inc. The Ocular Therapeutix logo, AXPAXLI™, ELUTYX™, and Ocular Therapeutix™ are trademarks of Ocular Therapeutix, Inc.